janssen presentation on centyrins, page-25

Back in march 2013, Centyrex CEO, Robert Hayes, was interviewed by Life Science Leader Magazine concerning the work of Centyrex(an alternative scaffold venture within Janssen R&D).

Last week 'Life Science Leader Magazine' did a follow-up:
Companies to watch: A Roundup of Life Science Developments and Technologies.

The following is the follow-up article relevant to Centyrex:

A company inside a company. Much of J&J’s pharma group consists of small units enveloped or overlapped with other parts of the organization. Centyrex has been an exception. It’s an entrepreneurial business more or less making it on its own as any other bio start-up. But having developed its novel molecular- scaffold Centyrin platform to the point of creating original products, it is becoming more integrated into the Janssen R&D Biotechnology Center of Excellence (BCE). Summarizing the company’s progress, CEO Robert Hayes says, “Centyrex has delivered on its goals to develop a therapeutic platform that complements the strengths Janssen R&D has in monoclonal antibodies.” The company remains vague about the therapeutic areas and entities it is pursuing, as reflected in its responses for the CtW Roundup below.

DEVELOPMENTS TO DATE

“making good progress on therapeutic targets in the oncology space”
“Janssen R&D made the decision to continue support of the Centyrex venture by transitioning the technology into the Janssen R&D BCE and expanding the use of the Centyrin platform.” That means Centyrex will essentially feed the pipeline with newer, early-stage products, handing them off to the BCE at the clinical development stage. The BCE has also assumed responsibility for Centyrin products already in development, as well as taking in a handful of Centyrex employees.

COMING IN 2014

“We look forward to further studying and progressing our work in oncology. We also look forward to applying the Centyrin technology to targeted therapies that have increased safety and efficacy.”
........................
Cheers
SoT